Framingham risk score associates with incident cancer and heart failure
The FRS associates with new-onset cancer or HF, implicating a broader clinical application of the FRS beyond ASCVD risk stratification in cardio-oncology.
Authors
- Bert van der Vegt (ORCID: https://orcid.org/0000-0002-2613-1506)
- Yvonne Koop (ORCID: https://orcid.org/0000-0001-6150-0859)
- Rudolf A. de Boer (ORCID: https://orcid.org/0000-0002-4775-9140)
- Stephan J. L. Bakker (ORCID: https://orcid.org/0000-0003-3356-6791)
- Navin Suthahar (ORCID: https://orcid.org/0000-0002-7781-2897)
- Pieter F. van den Berg (ORCID: https://orcid.org/0000-0003-1764-0242)
- Nabil Sayour
- Isabella Kardys (ORCID: https://orcid.org/0000-0002-2115-9745)
- Kevin Damman (ORCID: https://orcid.org/0000-0003-0190-2228)
- Laura I. Yousif
- Bart J. van Essen (ORCID: https://orcid.org/0000-0002-9057-7449)
- Adriaan A. Voors (ORCID: https://orcid.org/0000-0002-5417-4415)
- Wouter C. Meijers (ORCID: https://orcid.org/0000-0002-3287-6766)
- Yiqian Yang (ORCID: https://orcid.org/0009-0005-4002-997X)
- Ezgi Ünlü (ORCID: https://orcid.org/0000-0001-6355-8333)
- Thomas Kok (ORCID: https://orcid.org/0009-0002-8772-3924)
Institutions
- Semmelweis University (HU)
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- University Medical Center Utrecht (NL)
- Gottsegen National Cardiovascular Center (HU)
- Erasmus MC Cancer Institute (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1093/eurjpc/zwaf618
- Citations
- 2
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Bristol-Myers Squibb
- AstraZeneca
- ZonMw
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Novo Nordisk
- Astellas Pharma
- Universitair Medisch Centrum Groningen
- Daiichi Sankyo Europe